Advanced HIV Treatment in the Correctional Setting
August 15 - 17, 2008
Best Western - Gateway Grand
4200 NW 97th Boulevard
Gainesville, Florida 32606
Conference Program
Complete Program (PDF Version)
Speakers
 |
Jeffrey Beal, M.D. Clinical Director, Florida/Caribbean AETC; Associate Professor, University of South Florida; Medical Director, Ryan White Title III, Hendry/Glades County Health Departments; and Senior Physician, Lee County Health Department. |
 |
Ernesto J. Lamadrid, M.D. Director, HIV Services at the Alachua County Health Department; Adjunct Clinical Assistant Professor, University of Florida College of Nursing and Clinical Instructor Nova Southeastern University College of Medicine. He has twelve years of experience in Florida correctional medicine. Former Medical Director, Bureau of HIV/AIDS Florida Department of Health, and Florida/Caribbean AETC faculty member. |
 |
John P. May, M.D., F.A.C.P. Chief Medical Officer of Armor Correctional Health Services of Miami, Florida, Clinical Associate Professor of Medicine at NOVA Southeastern University College of Medicine in South Florida. |
 |
Swati R. Modi, M.D. Assistant Professor, University of Florida Center for HIV/AIDS Research, Education and Service (UF CARES), Pediatric Infectious Disease and Immunology, University of Florida College of Medicine, Jacksonville; Florida/Caribbean AETC faculty member. |
 |
Michael Thompson, Pharm.D., B.C.N.S.P. Assistant Dean for Clinical Affairs and Professor of Pharmacy Practice, College of Pharmacy and Pharmaceutical Sciences, Florida Agricultural and Mechanical University, Tallahassee, Florida. |
Sessions
Complications of Antiretroviral Therapy
Michael Thompson, Pharm.D., B.C.N.S.P.
The speaker will review the currently available antiretroviral agents including mechanism of action, common side effects and toxicities. He will also review common interactions with frequently prescribed drugs in this population. (Slides)
Resistance Interpretation
Ernesto J. Lamadrid, M.D.
The advances in the science of HIV allow us to identify the mutations present when a patient fails antiretroviral therapy. The resistance tests available today are genotype and phenotype. During this session we will learn the basics of these tests, how/when to use them in clinical practice and how to interpret them. We will also review the most common mutations related to the specific antiretroviral. (Slides)
DHHS Revised Guidelines 1/29/2008
Swati Modi, M.D.
The goal of this talk is to review the current DHHS Guidelines for the use of Antiretroviral Agent in HIV-infected Adults and Adolescents, and provide information regarding the reasons for the recommendations. Information will be provided to help participants better understand when to start antiretroviral therapy; what antiretroviral combinations should be used and which should be avoided; and when and how to use resistance testing. Special issues in HIV therapy are included such as treatment interruption and acute anti-retroviral syndrome. (Slides)
Changing Antiretroviral Therapy
Ernesto J. Lamadrid, M.D.
The treatment of HIV has changed substantially over the past 15 years and multiple new medications have been approved to add to the arsenal for treatment of those infected with HIV. During this session we will review several reasons to change therapy and the role the new agents play in ART. (Slides)
Tuberculosis and HIV
John P. May, M.D., F.A.C.P.
TB is the leading cause of death among HIV-infected individuals worldwide and poses particular risks in correctional settings. Diagnosing and treating HIV-infected individuals for TB infection and disease can pose challenges to the clinician. Newly identified extensively drug resistant strains of TB are threatening to destabilize TB control efforts globally. In this session, the speaker will discuss the global impact of tuberculosis, including Caribbean prisons, and review treatment of latent TB infection and active TB disease. The speaker will also discuss issues such as timing of initiation of antiretroviral therapy in relation to TB therapy, drug-drug interactions, and resistance. (Slides)
OI Prophylaxis and Treatment/Unusual Presentations
Ernesto J. Lamadrid, M.D.
This session will introduce the audience to the wide variety of infections encountered in immunocompromised patients. The diagnosis, treatment, and prognosis of PCP, toxoplasmosis, CMV, MAC, TB, cryptococcosis, and Candidiasis will be discussed in depth. In addition, prophylactic approaches will also be addressed. The lecture will enable the participant to attain a more profound level of understanding of potential drug interactions while managing multiple concurrent infections. (Slides)
Hepatitis B and C Management
Jeffrey A. Beal, M.D.
As the long-term survival in HIV infection has improved, chronic illnesses such as hepatitis have emerged as significant agents of co-morbidity and early mortality. The speaker will present an overview of the epidemiology of viral hepatitis in HIV and recommendations for screening and prevention. Treatment of hepatitis B and C continues to evolve, especially in HIV. (Slides)
